MiMedx Group, Inc $MDXG Stock Position Cut by Trigran Investments Inc.

Trigran Investments Inc. lowered its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 20.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,163,384 shares of the company’s stock after selling 1,537,644 shares during the quarter. MiMedx Group accounts for 8.2% of Trigran Investments Inc.’s portfolio, making the stock its 5th largest position. Trigran Investments Inc.’s holdings in MiMedx Group were worth $41,726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. bought a new position in MiMedx Group in the fourth quarter worth approximately $98,000. Barclays PLC raised its position in MiMedx Group by 7.6% in the fourth quarter. Barclays PLC now owns 375,625 shares of the company’s stock worth $2,543,000 after acquiring an additional 26,567 shares during the period. Nantahala Capital Management LLC raised its position in MiMedx Group by 64.8% in the fourth quarter. Nantahala Capital Management LLC now owns 2,416,389 shares of the company’s stock worth $16,359,000 after acquiring an additional 949,823 shares during the period. Marshall Wace LLP raised its position in MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after acquiring an additional 1,238,132 shares during the period. Finally, Stifel Financial Corp raised its position in MiMedx Group by 818.9% in the fourth quarter. Stifel Financial Corp now owns 171,235 shares of the company’s stock worth $1,159,000 after acquiring an additional 152,600 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

MDXG stock opened at $3.60 on Monday. MiMedx Group, Inc has a 12 month low of $3.03 and a 12 month high of $7.99. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $3.62 and a 200 day moving average price of $4.91. The stock has a market cap of $536.22 million, a PE ratio of 18.00 and a beta of 1.48.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. Equities research analysts anticipate that MiMedx Group, Inc will post -0.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings downgraded shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Wall Street Zen cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating for the company. Cantor Fitzgerald cut their target price on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Finally, UBS Group set a $10.00 target price on shares of MiMedx Group in a research note on Monday, February 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.